Trial Profile
A 16 Week Randomised, Open-labelled, Four-armed, Treat-to-target, Parallel-group Trial Comparing SIBA D Once Daily, SIBA E Once Daily, SIBA D Monday, Wednesday and Friday and Insulin Glargine Once Daily, All in Combination With Metformin in Subjects With Type 2 Diabetes Failing on OAD Treatment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin degludec (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 14 Mar 2013 Planned number of patients changed from 236 to 342 as reported by Clinical Trials Registry - India.
- 24 Sep 2010 Results presented at the 46th Annual Meeting of the European Association for the Study of Diabetes.
- 25 Jun 2010 Results have been presented at the 70th Scientific Sessions of the American Diabetes Association (ADA), according to a Novo Nordisk media release.